Evidence map›Paper›PMID 41356854›Full record

ArticleCureus2025

Autoimmune Nodopathy With Anti-Neurofascin 186 Antibody.

Ashik Anilkumar, Parameswaran Krishnan

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ashik AnilkumarNeurology, Indo American Hospital Brain and spine Center, Vaikom, IND.
Parameswaran KrishnanNeurology, Indo American Hospital Brain and Spine Center, Vaikom, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune neuropathy is a distinct subclass of immune-mediated neuropathy with a unique antibody-mediated profile. Early recognition is crucial for relief from the symptoms. The aim of this report was to highlight the clinical presentation and diagnostic and therapeutic challenges in a case of anti-neurofascin 186 nodopathy. A 46-year-old woman presented with progressive weakness in the lower limbs and pain in the palms and soles lasting for two years. She failed to respond to intravenous immunoglobulin and tapering steroids. Later, she was started on rituximab and showed significant neurological improvement over time. The findings indicate that early antibody testing can guide the effective management of autoimmune nodopathy.

Indexed as

anti-neurofascin 186 antibodyautoantibody profilingautoimmune nodopathyimmune-mediated neuropathyimmunotherapyrituximab therapy

Identifiers

PMID41356854
PMCPMC12678867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.